Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
31. January 2013
Novozymes acquires Iogen Bio-Products, the industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million).
21. January 2013
Organic sales growth was 4% (7% DKK, 3% LCY) compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million exceeded the outlook.
1. April 2013
26. February 2013
| Copyright © 2010 Novozymes. All Rights Reserved.